Shanghai Fosun Pharma (Group) SFOSF Stock
Shanghai Fosun Pharma (Group) Price Chart
Shanghai Fosun Pharma (Group) SFOSF Financial and Trading Overview
| Shanghai Fosun Pharma (Group) stock price | 2.2 USD |
| Previous Close | 2.18 USD |
| Open | 2.2 USD |
| Bid | 2.05 USD x 30000 |
| Ask | 2.3 USD x 30000 |
| Day's Range | 2.2 - 2.2 USD |
| 52 Week Range | 1.93 - 3.3 USD |
| Volume | 100 USD |
| Avg. Volume | 112 USD |
| Market Cap | 8.28B USD |
| Beta (5Y Monthly) | 0.382 |
| PE Ratio (TTM) | 12.222222 |
| EPS (TTM) | 0.18 USD |
| Forward Dividend & Yield | 0.06 (2.64%) |
| Ex-Dividend Date | July 16, 2026 |
| 1y Target Est | N/A |
SFOSF Valuation Measures
| Enterprise Value | 43.48B USD |
| Trailing P/E | 12.222222 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.19436686 |
| Price/Book (mrq) | 0.7957987 |
| Enterprise Value/Revenue | 1.021 |
| Enterprise Value/EBITDA | 7.368 |
Trading Information
Shanghai Fosun Pharma (Group) Stock Price History
| Beta (5Y Monthly) | 0.382 |
| 52-Week Change | -34.090% |
| S&P500 52-Week Change | 12.83% |
| 52 Week High | 3.3 USD |
| 52 Week Low | 1.93 USD |
| 50-Day Moving Average | 2.25 USD |
| 200-Day Moving Average | 2.39 USD |
SFOSF Share Statistics
| Avg. Volume (3 month) | 112 USD |
| Avg. Daily Volume (10-Days) | 10 USD |
| Shares Outstanding | 551.94M |
| Float | 1.63B |
| Short Ratio | N/A |
| % Held by Insiders | 14.66% |
| % Held by Institutions | 25.72% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.39 |
| Trailing Annual Dividend Yield | 17.93% |
| 5 Year Average Dividend Yield | 214.00% |
| Payout Ratio | 0.2529 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 7.96% |
| Operating Margin (ttm) | 4.87% |
| Gross Margin | 50.61% |
| EBITDA Margin | 13.85% |
Management Effectiveness
| Return on Assets (ttm) | 1.39% |
| Return on Equity (ttm) | 6.94% |
Income Statement
| Revenue (ttm) | 42.59B USD |
| Revenue Per Share (ttm) | 16.13 USD |
| Quarterly Revenue Growth (yoy) | 2.70% |
| Gross Profit (ttm) | 21.56B USD |
| EBITDA | 5.9B USD |
| Net Income Avi to Common (ttm) | 3.39B USD |
| Diluted EPS (ttm) | 0.18 |
| Quarterly Earnings Growth (yoy) | -9.19% |
Balance Sheet
| Total Cash (mrq) | 16.05B USD |
| Total Cash Per Share (mrq) | 6.08 USD |
| Total Debt (mrq) | 39.11B USD |
| Total Debt/Equity (mrq) | 61.69 USD |
| Current Ratio (mrq) | 0.902 |
| Book Value Per Share (mrq) | 2.7645183 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 5.5B USD |
| Levered Free Cash Flow (ttm) | 2.26B USD |
Profile of Shanghai Fosun Pharma (Group)
| Country | United States |
| State | N/A |
| City | Shanghai |
| Address | Building A |
| ZIP | 200233 |
| Phone | 86 21 3398 7000 |
| Website | https://www.fosunpharma.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 40684 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Q&A For Shanghai Fosun Pharma (Group) Stock
What is a current SFOSF stock price?
Shanghai Fosun Pharma (Group) SFOSF stock price today per share is 2.2 USD.
How to purchase Shanghai Fosun Pharma (Group) stock?
You can buy SFOSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shanghai Fosun Pharma (Group)?
The stock symbol or ticker of Shanghai Fosun Pharma (Group) is SFOSF.
Which industry does the Shanghai Fosun Pharma (Group) company belong to?
The Shanghai Fosun Pharma (Group) industry is Drug Manufacturers - Specialty & Generic.
How many shares does Shanghai Fosun Pharma (Group) have in circulation?
The max supply of Shanghai Fosun Pharma (Group) shares is 3.76B.
What is Shanghai Fosun Pharma (Group) Price to Earnings Ratio (PE Ratio)?
Shanghai Fosun Pharma (Group) PE Ratio is 12.22222200 now.
What was Shanghai Fosun Pharma (Group) earnings per share over the trailing 12 months (TTM)?
Shanghai Fosun Pharma (Group) EPS is 0.18 USD over the trailing 12 months.
Which sector does the Shanghai Fosun Pharma (Group) company belong to?
The Shanghai Fosun Pharma (Group) sector is Healthcare.
